Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, T-Cell, Peripheral 2Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Hodgkin Disease 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32venetoclax 31Etoposide 31Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × sintilimab × Lymphoid × Clear all
NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡